ArticleFrontiers in microbiology2022
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Mocravimod as a repurposing drug against clinical isolates ofMicrobiology spectrum · 2026Article
- Drug repurposing: antimicrobial and antibiofilm effects of MLS0315771 against Gram-positive bacteria.BMC microbiology · 2026Article
- Antibacterial effects of BB-Cl-Amidine against multidrug-resistant Gram-positive pathogens via membrane disruption.The Journal of antibiotics · 2026Article
- Repurposing AZD-5991 for inhibiting growth and biofilm formation of Staphylococcus aureus by disrupting the cell membrane and targeting FabI.BMC microbiology · 2025Article
- Nature's Arsenal: Uncovering Antibacterial Agents Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- In vitro antibacterial and antibiofilm activities of isobavachalcone against Enterococcus faecalis clinical isolates from China.BMC microbiology · 2025Article
- Gold Nanoparticles Functionalized With 5-Amino-2-Mercaptobenzimidazole: A Promising Antimicrobial Strategy Against Carbapenem-Resistant Gram-Negative Bacteria.International journal of nanomedicine · 2025Article
- AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria.Emerging microbes & infections · 2024Article
- Medicinally Privileged Natural Chalcones: Abundance, Mechanisms of Action, and Clinical Trials.International journal of molecular sciences · 2024Review
- Synthesis, Antibacterial Effects, and Toxicity of Licochalcone C.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Proteomic study of the inhibitory effects of tannic acid on MRSA biofilm.Frontiers in pharmacology · 2024Article
- The potential target of bithionol against Staphylococcus aureus: design, synthesis and application of biotinylated probes Bio-A2.The Journal of antibiotics · 2023Article
- Article
- Licochalcone A Induces Ferroptosis in Hepatocellular Carcinoma via Reactive Oxygen Species Activated by the SLC7A11/GPX4 Pathway.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.